Healthcare provider profile · identity verified

Luis Ramirez, APRN

Nurse Practitioner · MIAMI, FL · NPI 1871128579

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1010	325
Losartan Potassium	Losartan Potassium	435	139
Diclofenac Sodium	Diclofenac Sodium	395	134
Lisinopril	Lisinopril	393	120
Amlodipine Besylate	Amlodipine Besylate	343	112
Metformin Hcl	Metformin Hcl	298	96
Hydrochlorothiazide	Hydrochlorothiazide	296	90
Omeprazole	Omeprazole	290	78
Gabapentin	Gabapentin	280	93
Levothyroxine Sodium	Levothyroxine Sodium	240	63
Famotidine	Famotidine	191	55
Rosuvastatin Calcium	Rosuvastatin Calcium	188	68
Ezetimibe	Ezetimibe	172	58
Tamsulosin Hcl	Tamsulosin Hcl	159	59
Metoprolol Succinate	Metoprolol Succinate	156	52
Ammonium Lactate	Ammonium Lactate	150	49
Alendronate Sodium	Alendronate Sodium	148	39
Fluticasone Propionate	Fluticasone Propionate	144	46
Januvia	Sitagliptin Phosphate	125	31
Glipizide	Glipizide	122	40
Metoprolol Tartrate	Metoprolol Tartrate	122	40
Albuterol Sulfate Hfa	Albuterol Sulfate	114	26
Baclofen	Baclofen	111	81
Pantoprazole Sodium	Pantoprazole Sodium	110	39
Triamcinolone Acetonide	Triamcinolone Acetonide	107	45
Ibuprofen	Ibuprofen	98	54
Meclizine Hcl	Meclizine Hcl	95	35
Montelukast Sodium	Montelukast Sodium	90	27
Allopurinol	Allopurinol	87	29
Sildenafil Citrate	Sildenafil Citrate	83	18
Vitamin D2	Ergocalciferol (Vitamin D2)	83	25
Ciclopirox	Ciclopirox	79	24
Ketoconazole	Ketoconazole	78	27
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	76	16
Farxiga	Dapagliflozin Propanediol	69	24
Meloxicam	Meloxicam	62	48
Eliquis	Apixaban	60	16
Carvedilol	Carvedilol	59	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	59	15
Enalapril Maleate	Enalapril Maleate	58	19
Clopidogrel	Clopidogrel Bisulfate	57	21
Trazodone Hcl	Trazodone Hcl	56	18
Hydroxyzine Pamoate	Hydroxyzine Pamoate	54	17
Furosemide	Furosemide	48	19
Symbicort	Budesonide/Formoterol Fumarate	48	suppressed
Atenolol	Atenolol	45	14
Escitalopram Oxalate	Escitalopram Oxalate	43	23
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	43	suppressed
Mupirocin	Mupirocin	41	25
Linzess	Linaclotide	40	suppressed
Nifedipine Er	Nifedipine	39	14
Azithromycin	Azithromycin	37	33
Ciprofloxacin Hcl	Ciprofloxacin Hcl	37	32
Chlorthalidone	Chlorthalidone	35	suppressed
Methylprednisolone	Methylprednisolone	35	32
Tadalafil	Tadalafil	33	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	31	11
Clotrimazole	Clotrimazole	30	15
Jardiance	Empagliflozin	30	suppressed
Latanoprost	Latanoprost	30	suppressed
Tradjenta	Linagliptin	30	suppressed
Cefuroxime	Cefuroxime Axetil	29	25
Clobetasol Propionate	Clobetasol Propionate	28	11
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	28	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	26	11
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Glipizide Er	Glipizide	25	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	25	suppressed
Finasteride	Finasteride	24	suppressed
Lumigan	Bimatoprost	23	suppressed
Folic Acid	Folic Acid	22	suppressed
Memantine Hcl	Memantine Hcl	22	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	22	17
Clonidine Hcl	Clonidine Hcl	21	suppressed
Diclofenac Potassium	Diclofenac Potassium	20	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	20	suppressed
Restasis	Cyclosporine	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	16
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	19	suppressed
Ozempic	Semaglutide	19	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	19	suppressed
Ciclopirox	Ciclopirox Olamine	18	suppressed
Glimepiride	Glimepiride	17	suppressed
Procto-Med Hc	Hydrocortisone	17	suppressed
Simvastatin	Simvastatin	17	suppressed
Synthroid	Levothyroxine Sodium	17	suppressed
Cephalexin	Cephalexin	16	16
Entresto	Sacubitril/Valsartan	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Tresiba Flextouch U-100	Insulin Degludec	16	suppressed
Atrovent Hfa	Ipratropium Bromide	15	suppressed
Metformin Hcl Er	Metformin Hcl	15	suppressed
Vascepa	Icosapent Ethyl	15	suppressed
Bumetanide	Bumetanide	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Permethrin	Permethrin	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	14	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Azelastine Hcl	Azelastine Hcl	13	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	13	suppressed
Diltiazem Hcl	Diltiazem Hcl	13	suppressed
Gemfibrozil	Gemfibrozil	13	suppressed
Humalog Kwikpen U-100	Insulin Lispro	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Unifine Pentips	Pen Needle, Diabetic	13	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	12	suppressed
Benazepril Hcl	Benazepril Hcl	12	suppressed
Dorzolamide-Timolol	Dorzolamide/Timolol/Pf	12	suppressed
Novolog Flexpen	Insulin Aspart	12	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	12	suppressed
Sure Comfort Pen Needle	Pen Needle, Diabetic	12	suppressed
Telmisartan	Telmisartan	12	suppressed
Valsartan	Valsartan	12	suppressed
Enulose	Lactulose	11	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	11	suppressed
Levemir Flexpen	Insulin Detemir	11	suppressed
Sertraline Hcl	Sertraline Hcl	11	suppressed
Veltassa	Patiromer Calcium Sorbitex	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error